Established and emerging uses of cytoprotection in head and neck cancer

Archives of Otolaryngology - Head and Neck Surgery

Volumn 132, Issue 2, 2006, Pages 129-130

  Rosenthal, David I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CISPLATIN;

CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CELL PROTECTION; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; DYSPHAGIA; EDITORIAL; ERYTHEMA; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHROTOXICITY; ONCOLOGY; OVARY CANCER; RADIATION DOSE; RADIATION RESPONSE; RISK BENEFIT ANALYSIS;

AMIFOSTINE; CYTOPROTECTION; HEAD AND NECK NEOPLASMS; HUMANS; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 33644826289     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.132.2.129     Document Type: Editorial

References (18)

1. Gralla RJ, Osoba D, Kris MG, et al; American Society of Clinical Oncology. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971-2994.
2. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20:4083-4107.
3. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590-2598.
4. Rosenthal DI. What is the role of amifostine in the management of head and neck squamous cell carcinoma? In: Perry MC, ed. ASCO Educational Book. Alexandria, Va: American Society of Clinical Oncology; 2005:429-435.
5. Rosenthal DI, Chambers MS, Weber RS, Eisbruch A. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Semin Oncol. 2004;31:25-28.
6. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14:2101-2112.
7. Schiller JH, Storer B, Berlin J, et al. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol. 1996;14:1913-1921.
8. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339-3345.
9. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999;17:3333-3355.
10. Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 Update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002;20:2895-2903.
11. Ozsahin M, Betz M, Matzinger O, et al. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy. Arch Otolaryngol Head Neck Surg. 2006;132:141-145.
12. Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol. 2000;18:2226-2233.
13. Anne PR. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Semin Oncol. 2002;29:80-83.
14. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:739-747.
15. Zouhair A, Azria D, Pasche P, et al. Accelerated postoperative radiotherapy with weekly concomitant boost in patients with locally advanced head and neck cancer. Radiother Oncol. 2004;70:183-188.
16. Adelstein DJ, Saxton JP, Lavertu P, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck. 1997;19:567-575.
17. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys. 2000;47:1-12.
18. Büntzel J, Kuttner K, Frohlich D, Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol. 1998;9:505-509.